Ryman Healthcare Limited
RHCGF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $714 | $651 | $560 | $504 |
| % Growth | 9.7% | 16.1% | 11.2% | – |
| Cost of Goods Sold | $0 | $652 | $580 | $502 |
| Gross Profit | $714 | -$1 | -$20 | $2 |
| % Margin | 100% | -0.2% | -3.5% | 0.4% |
| R&D Expenses | $0 | $16 | $12 | $5 |
| G&A Expenses | $512 | $414 | $177 | $306 |
| SG&A Expenses | $544 | $464 | $177 | $306 |
| Sales & Mktg Exp. | $32 | $50 | $0 | $0 |
| Other Operating Expenses | $288 | $256 | $440 | $751 |
| Operating Expenses | $832 | $720 | $216 | $710 |
| Operating Income | -$118 | -$70 | -$20 | $2 |
| % Margin | -16.6% | -10.7% | -3.5% | 0.4% |
| Other Income/Exp. Net | -$97 | -$75 | $226 | $720 |
| Pre-Tax Income | -$215 | -$145 | $206 | $722 |
| Tax Expense | $221 | -$150 | -$52 | $29 |
| Net Income | -$437 | $5 | $258 | $693 |
| % Margin | -61.2% | 0.7% | 46% | 137.5% |
| EPS | -0.61 | 0.007 | 0.5 | 1.31 |
| % Growth | -8,940.6% | -98.6% | -61.8% | – |
| EPS Diluted | -0.61 | 0.007 | 0.5 | 1.31 |
| Weighted Avg Shares Out | 710 | 688 | 516 | 530 |
| Weighted Avg Shares Out Dil | 710 | 688 | 516 | 530 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $0 |
| Interest Expense | $140 | $50 | $120 | $31 |
| Depreciation & Amortization | $48 | $44 | $47 | $36 |
| EBITDA | -$27 | -$51 | $458 | $788 |
| % Margin | -3.8% | -7.8% | 81.8% | 156.5% |